[Current strategies of primary therapy for breast cancer].
Active clinical researches for breast cancer advance the therapeutic strategies remarkably, however, it seems to be more difficult to choose the appropriate treatment based on the evidence for each patient due to its diversification. Moreover, the striking achievements of various molecular targeting drugs established by basic researches make it complex, since the biological feature of tumor cell must be considered carefully for drug selection. To make it straight, the latest strategies for breast cancer treatment based on both basic and clinical evidences are summarized, especially about surgical and medical treatments of primary therapy for breast cancer.
Hayashida
Tetsu
T
Department of Surgery, School of Medicine, Keio University.
Jinno
Hiromitsu
H
Sakata
Michio
M
Takahashi
Maiko
M
Kitagawa
Yuko
Y
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D008197:Lymph Node Excision; D008408:Mastectomy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018931:Antineoplastic Agents, Hormonal; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human